Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 8/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433707 | 1.00 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL7155003 | 1.00 | MME (0.59) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL29453232 | 0.99 | MME (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL10868042 | 0.91 | CAPN1 (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL30902886 | 0.91 | CTSK (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL30902885 | 0.91 | CTSK (0.58) | MMEECE1CTSKCASP1CAPN1 | |
| SCHEMBL3140616 | 0.91 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL614741 | 0.91 | CASP3 (0.62) | MMEECE1CTSKCASP1CASP3 | |
| SCHEMBL28645697 | 0.90 | CTSK (0.57) | CTSKCASP1PSMB8PSMB9PSMB5 | |
| SCHEMBL28645693 | 0.90 | MME (0.60) | MMEECE1CTSKCAPN1PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371478-A | Method for synthesizing amide and/or polypeptide by taking transient protection amino acid as ammonia component | 广州医科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-119137136-A | Dual-residue extension peptide and preparation method thereof | 国立大学法人东海国立大学机构 | 2024-12-13 | — | — | CN | disclosed |
| US-11946079-B2 | Method for producing a protein hydrolysate using an endopeptidase and a carboxypeptidase | NOVOZYMES A/S (DK) | 2024-04-02 | — | — | US | disclosed |
| US-20220127592-A1 | POLYPEPTIDE, USE AND METHOD FOR HYDROLYSING PROTEIN | NOVOZYMES A/S (DK) | 2022-04-28 | — | — | US | disclosed |
| EP-3142649-B1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITOR EMRICASAN | CONATUS PHARMACEUTICALS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3397251-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | Conatus Pharmaceuticals, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017117478-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1351975-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1091930-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000001666-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1998035982-A1 | COMPOUNDS FOR USE IN ADEPT | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CASP1, CASP5, CASP2 | MME 226/4885ECE1 648/4885CTSK 56/4885 |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | MME 269/4885ECE1 253/4885CTSK 692/4885 |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | MME 225/4885ECE1 194/4885CTSK 110/4885 |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | MME 269/4885ECE1 253/4885CTSK 692/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | MME 259/4885ECE1 234/4885CTSK 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.